MX2020005775A - Uso farmaceutico de pirfenidona para la reduccion de fibrosis cardiaca en pacientes con cardiomiopatia y/o esteatosis cardiaca y/o covid-19. - Google Patents

Uso farmaceutico de pirfenidona para la reduccion de fibrosis cardiaca en pacientes con cardiomiopatia y/o esteatosis cardiaca y/o covid-19.

Info

Publication number
MX2020005775A
MX2020005775A MX2020005775A MX2020005775A MX2020005775A MX 2020005775 A MX2020005775 A MX 2020005775A MX 2020005775 A MX2020005775 A MX 2020005775A MX 2020005775 A MX2020005775 A MX 2020005775A MX 2020005775 A MX2020005775 A MX 2020005775A
Authority
MX
Mexico
Prior art keywords
cardiac
covid
pirfenidone
cardiomyopathy
pharmaceutical use
Prior art date
Application number
MX2020005775A
Other languages
English (en)
Inventor
García Arturo Santos
Rodríguez Ana Soledad Sandoval
Borunda Juan Socorro Armendáriz
Cuevas Jorge Gutiérrez
Original Assignee
Centro De Retina Medica Y Quirurgica S C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Retina Medica Y Quirurgica S C filed Critical Centro De Retina Medica Y Quirurgica S C
Priority to MX2020005775A priority Critical patent/MX2020005775A/es
Priority to PCT/MX2021/000019 priority patent/WO2022015141A1/es
Publication of MX2020005775A publication Critical patent/MX2020005775A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente desarrollada, se encuentra relacionada al campo de los medicamentos que reducen la fibrosis cardíaca y también la expresión de la troponina I , concretamente al uso farmacéutico que contiene 5-metil -1-fenil -2-(1H) -piridona (Pirfenidona) como principio activo solo o en combinación con cualquier otra molécula bioactiva, concretamente para el manejo de pacientes con cardiomiopatía y/o esteatosis cardiaca y/o COVID-19.
MX2020005775A 2020-07-13 2020-07-13 Uso farmaceutico de pirfenidona para la reduccion de fibrosis cardiaca en pacientes con cardiomiopatia y/o esteatosis cardiaca y/o covid-19. MX2020005775A (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2020005775A MX2020005775A (es) 2020-07-13 2020-07-13 Uso farmaceutico de pirfenidona para la reduccion de fibrosis cardiaca en pacientes con cardiomiopatia y/o esteatosis cardiaca y/o covid-19.
PCT/MX2021/000019 WO2022015141A1 (es) 2020-07-13 2021-06-03 Uso farmacéutico de pirfenidona para la reducción de fibrosis cardiaca en pacientes con cardiomiopatía y/o esteatosis cardiaca y/o covid-19

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2020005775A MX2020005775A (es) 2020-07-13 2020-07-13 Uso farmaceutico de pirfenidona para la reduccion de fibrosis cardiaca en pacientes con cardiomiopatia y/o esteatosis cardiaca y/o covid-19.

Publications (1)

Publication Number Publication Date
MX2020005775A true MX2020005775A (es) 2022-01-14

Family

ID=79554854

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005775A MX2020005775A (es) 2020-07-13 2020-07-13 Uso farmaceutico de pirfenidona para la reduccion de fibrosis cardiaca en pacientes con cardiomiopatia y/o esteatosis cardiaca y/o covid-19.

Country Status (2)

Country Link
MX (1) MX2020005775A (es)
WO (1) WO2022015141A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US20190247373A1 (en) * 2016-07-14 2019-08-15 Children's Hospital Medical Center Methods for treating fibrosis
WO2018164098A1 (ja) * 2017-03-06 2018-09-13 国立大学法人大阪大学 心臓線維化モデルとして用いられる細胞集団、その製造方法、それを利用したスクリーニング方法及び心臓線維化モデルの評価方法、並びに心臓線維化モデルの評価システム
CN111481547A (zh) * 2020-04-16 2020-08-04 青岛海洋生物医药研究院股份有限公司 哌非尼酮或其药学上可接受的盐在制备预防和/或治疗新型冠状病毒炎症药物中的应用

Also Published As

Publication number Publication date
WO2022015141A1 (es) 2022-01-20

Similar Documents

Publication Publication Date Title
EP4506001A3 (en) SUBSTITUTED TETRAHYDROFURANS AS SODIUM CHANNEL MODULATORS
SA523450286B1 (ar) مركب 4-أمينو كوينازولين
WO2018022815A3 (en) Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs by in situ salt-to-neutral drug conversion of salt drug
MX2018010788A (es) Composicion oftalmologica.
MY208610A (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
ZA202303699B (en) Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate
SG10201902429PA (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
SA523440384B1 (ar) مركبات الفوسفوليبيدات واستخداماتها
MXPA05013637A (es) Inhibidores gsk-3 y usos de los mismos.
MY199903A (en) Combination therapy with controlled-release cnp agonists
IN2014DN08870A (es)
TW200609001A (en) Particulate-stabilized injectable pharmaceutical compositions of posaconasole
PH12020500324A1 (en) Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage
EA201691008A1 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-a]пиридо[3,4-e]пиримидин-5(1h)-он, его соли и способы применения
AU2015242791A1 (en) Drug Delivery Enhancer Comprising Substance For Activating Lysophospholipid Receptors
EP4591874A3 (en) Pharmaceutical development
ZA202101118B (en) A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis
JOP20170148A1 (ar) مثبطات Wnt لعلاج التليف
TN2019000220A1 (en) Intranasal composition comprising betahistine
AU2017370226A1 (en) Pharmaceutical composition containing insulin-like growth factor-2 and use thereof
MX2022012033A (es) Agente terapeutico para infeccion por coronavirus.
TN2023000279A1 (en) Oral solution based on citicoline and nicotinamide for use in the treatment of glaucoma
PH12012501261A1 (en) Piperazines as antimalarial agents
Cayla et al. Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC population
WO2021118199A3 (ko) P53을 활성화하는 펩타이드를 포함하는 조성물